Promoting personalised treatment
The aim of the PoCCardio project is to develop a point-of-care (PoC) tool which uses biological markers and polymorphisms from finger prick blood to help identify, classify and monitor patients with cardiovascular disease who are at high risk of further events.
The Tool
The portable device allows point-of-care (PoC) measurements of both proteomic biomarkers and genetic risk variants to improve overall management of high-risk patients.
Laboratory validation of the tool and biological markers will be undertaken, followed by a multinational clinical trial which will include existing and approved pharmaceuticals.
Health equity
The tool provides fast results independent of access to high-end care facilities and thereby helps increase social inclusiveness and stimulate acceptance.
Validation trials
The developed point-of-care tool will be tested and validated in two trials, involving patients at a high risk of recurrent cardiovascular events
Trial 2: Multinational clinical trial involving 1800+ people with recent myocardial infarction
The clinical, biochemical and genetic data generated in the PoCCardio clinical trial are used to develop a computational AI-based tool for predicting the risk of a heart attack and therapy response in patients.
13 out of 29 study centres in Austria, Germany and Poland have begun recruiting participants for the trial of the PoCCardio point-of-care solution.
The journal paper is co-authored by the Medical University of Graz for MDPI Biomedicines
PoCCardio Project
Personalised Medicine by using an Advanced Point-of-Care Tool for Stratified Treatment in High Risk Cardiovascular Patients
